 NEW YORK, June 23, 2021 PRNewswire -- AIkido Pharma Inc. Nasdaq: AIKI AIkido or the Company today announced that the Company has filed a provisional patent application for the use of ketamine and peptides to treat Alzheimers disease. The Company previously secured and announced the acquisition of patent rights for use of peptides as a drug delivery system. 